Primary Outcome Measures
Cohort 1 and 3: Radiographic Progression Free Survival (rPFS) [Time Frame: Up to 28 months] [Designated as safety issue: ]
Secondary Outcome Measures
Cohort 1: Overall survival (OS) [Time Frame: Up to 66 months] [Designated as safety issue: ]
Cohort 1: Time to Symptomatic Progression [Time Frame: Up to 28 months] [Designated as safety issue: ]
Cohort 1: Time to Initiation of Cytotoxic Chemotherapy [Time Frame: Up to 28 months] [Designated as safety issue: ]
Cohort 1: Observed Plasma Concentrations of Niraparib [Time Frame: Cycle 2 to 7; Each Cycle is of 28 days (Up to 7 months)] [Designated as safety issue: ]
Cohort 1: Observed Trough Plasma Concentrations of Abiraterone [Time Frame: Cycles 2 and 3; Each Cycle is of 28 days (Up to 3 months)] [Designated as safety issue: ]
Cohort 1: Number of Participants with Treatment-Emergent Adverse events (TEAEs) [Time Frame: Up to 66 months] [Designated as safety issue: ]
Cohort 1: Number of Participants with Treatment-Emergent Adverse events by Severity [Time Frame: Up to 66 months] [Designated as safety issue: ]
Cohort 1: Number of Participants with Laboratory Abnormalities as Measure of Safety [Time Frame: Up to 66 months] [Designated as safety issue: ]